We understand the pressure facing diagnostic companies after securing funding or pharma partnerships. Your investor presentations included aggressive timelines. Your board expects execution. Every month of delay erodes competitive advantage and consumes capital without generating revenue.
Our integrated approach directly addresses this challenge. Because lateral flow development, scale-up, manufacturing, and regulatory support operate under one roof, you avoid the coordination delays inherent in managing multiple vendors across different organisations and time zones. Technical questions don’t require scheduling international calls; they get resolved by teams working in adjacent buildings.
This integrated approach compresses concept-to-commercial timelines compared to fragmented CDMO relationships. In markets where category leadership often goes to the first company with a validated product, this advantage can be decisive for long-term success.
